Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"
20-12-15 AMAG Pharmaceuticals : Files Submission in Response to the Food and Drug Administration's Notice of Opportunity for a Hearing and Proposal to Withdraw Approval of Makena AQ
20-12-14 AMAG Pharmaceuticals : Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection) PU
20-11-17 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
20-11-17 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
20-11-16 AMAG Pharmaceuticals : Covis Group Completes Acquisition of AMAG Pharmaceuticals AQ
Manager TitleAgeSince
Director of Finance/CFO - -
President 52 -
Corporate Secretary - -
Director TitleAgeSince
Director/Board Member 52 -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap.
20-11-15Issuer sale

Chairman

136,253 0.3949%
20-11-15
Caligan Partners LP
Issuer saleCompany 3,499,428 10.1425%
20-11-15Issuer sale

Chief Executive Officer

1,000,000 2.8983%
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%+0.29% - - 477M
-0.73%+5.34%+40.78%+154.77% 1,013B
+0.63%+6.83%+52.44%+49.05% 574B
-0.21%+3.60%+18.71%+62.79% 397B
+0.12%+4.97%+21.24%+15.95% 324B
+0.79%+0.09%+24.39%+14.67% 280B
+1.57%+4.13%+24.35%+32.78% 273B
-1.98%-0.14%+15.10%+54.38% 182B
-1.05%-1.25%-45.75%-48.76% 194B
-3.20%-5.82%+10.35%+55.50% 151B
Average -0.37%+2.65%+17.95%+43.46% 376.52B
Weighted average by Cap. -0.15%+3.99%+27.93%+69.94%
Logo AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.
Employees
-
  1. Stock Market
  2. Stocks
  3. AMAG Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!